Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.44 |
| ▸ | RAB9A | P51151 | 10/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225540 | 0.90 | CYP2C9 (0.47) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10312510 | 0.88 | CYP2C9 (0.45) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4548371 | 0.80 | CYP2C9 (0.62) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14349862 | 0.77 | CYP1A2 (0.58) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4548382 | 0.77 | CYP1A2 (0.62) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10312511 | 0.71 | CYP2C9 (0.53) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4548372 | 0.69 | CYP2C9 (0.68) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4548367 | 0.69 | CA12 (0.47) | NPC1RAB9ASMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL24529065 | 0.68 | MAOB (0.48) | HSD17B10 | |
| SCHEMBL14349859 | 0.67 | HCAR2 (0.79) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | NPC1 20/4885RAB9A 2584/4885SMN1; SMN2 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.